TD Asset Management Inc Has $282.42 Million Position in Johnson & Johnson $JNJ

TD Asset Management Inc decreased its stake in Johnson & Johnson (NYSE:JNJ) by 1.8% in the 3rd quarter, HoldingsChannel reports. The institutional investor owned 1,523,132 shares of the company’s stock after selling 28,172 shares during the period. TD Asset Management Inc’s holdings in Johnson & Johnson were worth $282,419,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently made changes to their positions in JNJ. Vanguard Group Inc. lifted its position in shares of Johnson & Johnson by 1.3% in the 2nd quarter. Vanguard Group Inc. now owns 237,047,859 shares of the company’s stock worth $36,209,060,000 after purchasing an additional 3,085,180 shares during the period. Geode Capital Management LLC raised its stake in Johnson & Johnson by 2.1% during the second quarter. Geode Capital Management LLC now owns 60,609,476 shares of the company’s stock worth $9,227,988,000 after buying an additional 1,225,676 shares during the last quarter. Norges Bank acquired a new position in Johnson & Johnson in the second quarter valued at $4,877,174,000. Bank of New York Mellon Corp grew its holdings in Johnson & Johnson by 3.5% during the 3rd quarter. Bank of New York Mellon Corp now owns 24,637,649 shares of the company’s stock worth $4,568,313,000 after acquiring an additional 835,146 shares during the period. Finally, Charles Schwab Investment Management Inc. lifted its stake in shares of Johnson & Johnson by 0.3% in the 2nd quarter. Charles Schwab Investment Management Inc. now owns 18,951,337 shares of the company’s stock valued at $2,894,979,000 after purchasing an additional 52,074 shares during the period. 69.55% of the stock is owned by institutional investors and hedge funds.

Johnson & Johnson Price Performance

JNJ opened at $246.21 on Wednesday. Johnson & Johnson has a 1 year low of $141.50 and a 1 year high of $247.25. The company has a debt-to-equity ratio of 0.48, a current ratio of 1.03 and a quick ratio of 0.77. The company has a market capitalization of $593.35 billion, a price-to-earnings ratio of 22.28, a P/E/G ratio of 2.39 and a beta of 0.35. The firm’s fifty day moving average price is $222.42 and its two-hundred day moving average price is $200.48.

Johnson & Johnson (NYSE:JNJ) last released its earnings results on Saturday, January 31st. The company reported $2.46 earnings per share (EPS) for the quarter. The company had revenue of $24.28 billion during the quarter. Johnson & Johnson had a return on equity of 33.04% and a net margin of 28.46%. As a group, analysts anticipate that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, March 10th. Stockholders of record on Tuesday, February 24th will be paid a $1.30 dividend. The ex-dividend date is Tuesday, February 24th. This represents a $5.20 annualized dividend and a dividend yield of 2.1%. Johnson & Johnson’s dividend payout ratio (DPR) is presently 47.06%.

Insider Activity at Johnson & Johnson

In related news, EVP Timothy Schmid sold 22,623 shares of Johnson & Johnson stock in a transaction that occurred on Wednesday, February 18th. The shares were sold at an average price of $244.33, for a total value of $5,527,477.59. Following the completion of the transaction, the executive vice president directly owned 26,769 shares in the company, valued at approximately $6,540,469.77. The trade was a 45.80% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Vanessa Broadhurst sold 6,197 shares of the stock in a transaction on Tuesday, February 17th. The stock was sold at an average price of $243.39, for a total value of $1,508,287.83. Following the sale, the executive vice president owned 23,003 shares in the company, valued at approximately $5,598,700.17. This represents a 21.22% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders sold 30,142 shares of company stock valued at $7,360,528. 0.16% of the stock is owned by insiders.

Analysts Set New Price Targets

Several analysts have recently commented on the stock. Wolfe Research raised their price objective on shares of Johnson & Johnson from $225.00 to $240.00 and gave the stock an “outperform” rating in a research report on Monday, January 5th. TD Cowen increased their price objective on shares of Johnson & Johnson from $222.00 to $250.00 and gave the stock a “buy” rating in a research report on Thursday, January 22nd. Freedom Capital downgraded Johnson & Johnson from a “strong-buy” rating to a “hold” rating in a research note on Friday, January 16th. HSBC increased their price target on Johnson & Johnson from $240.00 to $265.00 and gave the stock a “buy” rating in a report on Friday, January 30th. Finally, Morgan Stanley set a $262.00 price objective on Johnson & Johnson and gave the company an “overweight” rating in a report on Wednesday, January 28th. One research analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and nine have issued a Hold rating to the stock. Based on data from MarketBeat.com, Johnson & Johnson currently has an average rating of “Moderate Buy” and an average target price of $232.70.

Johnson & Johnson News Roundup

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: FDA pipeline upside — J&J submitted an sBLA for IMAAVY (nipocalimab) as the first potential FDA‑approved therapy for warm autoimmune hemolytic anemia, giving Janssen a new, high‑margin specialty indication with meaningful unmet need. JNJ seeks FDA approval of IMAAVY (PR Newswire)
• Positive Sentiment: Clinical proof supports growth — new three‑year TREMFYA ulcerative colitis data reinforce J&J’s ability to replace legacy Stelara sales, underpinning revenue/earnings guidance and investor confidence in the Innovative Medicine segment. TREMFYA three‑year data (MSN)
• Positive Sentiment: Potential asset sale could unlock value — reports J&J is exploring a sale of DePuy Synthes (orthopedics) as part of its separation plans; a major divestiture would raise cash and simplify the portfolio, which investors tend to reward. Potential DePuy sale (InsiderMonkey)
• Neutral Sentiment: Analyst and options activity is creating noise — Wall Street coverage is generally constructive but mixed (price targets/ratings vary) and unusual options flows are elevating short‑term volatility without a clear directional signal. Wall Street optimism (Zacks)
• Neutral Sentiment: Strategic partnerships (e.g., first co‑funding with Blackstone) are notable but their near‑term earnings impact is unclear. Co‑funding with Blackstone (TipRanks)
• Negative Sentiment: Legal overhang — Bayer filed a lawsuit over prostate‑cancer drug claims (Nubeqa), adding litigation risk that can pressure sentiment in the biotech/pharma unit. Bayer sues J&J (Reuters)
• Negative Sentiment: Today’s ex‑dividend technical effect — Feb. 24 was the ex‑dividend date for JNJ’s $1.30 quarterly payout, so the share price is likely to show a mechanical decline equal to the dividend amount, which can look like a sell‑off even when fundamentals are intact. Ex‑dividend note (MarketBeat)
• Negative Sentiment: Insider selling disclosed — EVP Timothy Schmid sold shares (Form 4 filings); routine disposals can be read negatively by some traders, adding modest near‑term pressure. Form 4 (SEC)

Johnson & Johnson Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.